|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
Netherlands Trial Register |
|
Last refreshed on:
|
28 April 2013 |
|
Main ID: |
NTR909 |
|
Date of registration:
|
16/02/2007 |
|
Primary sponsor: |
|
|
Public title:
|
The marker study
|
|
Scientific title:
|
Markers of endothelial activation and damage in haematological patients in relation to efficacy of transfusion support: a pilot study. - the marker study |
|
Date of first enrolment:
|
1/4/2007 |
|
Target sample size:
|
40 |
|
Recruitment status: |
pending |
|
URL:
|
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=909 |
|
Study type:
|
intervention |
|
Study design:
|
Randomised: No; Masking: None; Control: Not applicable; Group: Parallel; Type: -
|
|
|
Countries of recruitment
|
|
The Netherlands
| | | | | | | |
|
Contacts
|
|
Name:
|
J.L.H.
Kerkhoffs |
|
Address:
|
HagaHospital,
Leyweg 275
2545 CH
Den Haag
The Netherlands |
|
Telephone:
|
+31 (0)70 3592004 |
|
Email:
|
J.Kerkhoffs@hagaziekenhuis.nl |
|
Affiliation:
|
|
|
|
Name:
|
A.
Brand |
|
Address:
|
Leiden University Medical Center (LUMC),
P.0. Box 2184
2301 CD
Leiden
The Netherlands |
|
Telephone:
|
+31 (0)71 5685053 |
|
Email:
|
Anneke.Brand@bloodrtd.nl |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Age > 18 years;
2. Hemato-oncological disease;
3. Sickle cell disease;
4. Informed consent
Exclusion criteria: 1. Active cardiovascular disease;
2. Recent thrombo-embolism.
Age minimum:
Age maximum:
Gender:
|
|
Health Condition(s) or Problem(s) studied
|
Hemato-oncological patients, Sickle cell disease, Hematological patients
|
|
Primary Outcome(s)
|
|
Efficacy of platelet transfusion or red blood cell exchange transfusion in hemato-oncological patients and sickle cell patients, respectively, in relation to several endothelial activation markers.
|
|
Secondary ID(s)
|
|
ISRCTN35472475
|
|
N/A
|
|
Source(s) of Monetary Support
|
|
Sanquin Southwest
|
|